Customization: | Available |
---|---|
CAS No.: | 103177-37-3 |
Formula: | C27h23n5o4 |
Suppliers with verified business licenses
Audited by an independent third-party inspection agency
CAS Number | 103177-37-3 |
Synonyms | PRANLUKAST;4-oxo-8-(4-(4-phenylbutoxy)benzoylamino)-2-(tetrazol-5-yl)-4h-1-benzopyranh;benzamide,n-(4-oxo-2-(1h-tetrazol-5-yl)-4h-1-benzopyran-8-yl)-4-(4-phenylbutox;emihydrate;ONO-RS-411;ONO-RS-411-01;N-[4-keto-2-(2H-tetrazol-5-yl)chromen-7-yl]-4-(4-phenylbutoxy)benzamide;N-[4-oxo-2-(2H-1,2,3,4-tetrazol-5-yl)chromen-7-yl]-4-(4-phenylbutoxy)benzamide |
Product Name | Pranlukast |
Appearance | White Powder |
Molecular formula | C27H23N5O4 |
Molecular weight | 481.5 |
EINECS Number | 808-178-9 |
Pranlukast, a novel chromone derivative, was introduced in Japan for the treatment of bronchial asthma and allergic diseases. Pranlukast is a highly potent, selective and competitive antagonist of peptidoleukotrienes with high affinity for the LTD4 receptor. In patients with bronchial asthma, pranlukast was reported to induce significant improvement in both immediate and late asthmatic response induced by antigen. Pranlukast is also being evaluated clinically for the treatment of perennial allergic rhinitis, pediatric asthma, and cutaneous pruritus in dialysis patients. The therapeutic potential of pranlukast in managing irritable bowel syndrome has been suggested.
Application:A potent, selective and orally active CysLT receptor antagonist. Leukotriene antagonist. Used as an antiasthmatic